0 items USD 0.00Page not found
×
Error message
The page you requested does not exist. For your convenience, a search was performed using the query delveinsight cushings syndrome epidemiology forecast 2023.Your search for "" gave back 1517531 results.
“Diabetic Foot Ulcer (DFU) Pipeline Analysis” gives comprehensive insights on the various drugs being developed for the treatment of DFU. The report...
Catalog:
IQ4I
December 2018
Price: USD 3,600.00
Cyclin Dependent Kinase 2 - Pipeline Review, H2 2020 Summary Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2...
Catalog:
Global Markets Direct
November 2020
Price: USD 3,500.00
Signifor is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are...
Catalog:
MRRPB5
September 2023
Price: USD 2,900.00
Pasireotide is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are...
Catalog:
MRRPB5
September 2023
Price: USD 2,900.00
Ketoconazole is an antifungal medication used to treat a number of fungal infections. Applied to the skin it is used for fungal skin infections such...
Catalog:
MRRPB5
May 2023
Price: USD 2,900.00
Type 2 Diabetes (T2D) Pipeline Analysis” gives comprehensive insight on the various drugs being developed for the treatment of T2D. The global Type 2...
Catalog:
IQ4I
July 2015
Price: USD 3,600.00
Signifor is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are...
Catalog:
MRRPB5
September 2023
Price: USD 2,900.00
Pasireotide is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are...
Catalog:
MRRPB5
September 2023
Price: USD 2,900.00
Signifor is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are...
Catalog:
MRRPB5
January 2024
Price: USD 2,900.00
Pasireotide is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are...
Catalog:
MRRPB5
January 2024
Price: USD 2,900.00
“Non-alcoholic steatohepataitis (NASH) Pipeline Analysis” gives comprehensive insights on the various drugs being developed for the treatment of NASH...
Catalog:
IQ4I
August 2018
Price: USD 3,600.00
“Non-alcoholic steatohepataitis (NASH) Pipeline Analysis” gives comprehensive insights on the various drugs being developed for the treatment of NASH...
IQ4I
October 2019
Price: USD 3,600.00
Signifor is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are...
Catalog:
MRRPB5
January 2024
Price: USD 2,900.00
Pasireotide is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are...
Catalog:
MRRPB5
January 2024
Price: USD 2,900.00
Non-alcoholic steatohepataitis (NASH) Pipeline Analysis” gives comprehensive insights on the various drugs being developed for the treatment of NASH...
Catalog:
IQ4I
February 2017
Price: USD 3,600.00
